Pharma-Bio Serv, Inc. SEC 10-Q Report
Pharma-Bio Serv, Inc., a consulting firm specializing in the pharmaceutical, chemical, medical device, and biotechnology industries, has released its Form 10-Q report for the third quarter of 2025. The report provides a detailed overview of the company's financial performance and operational highlights, showcasing improved margins and operational efficiency despite a decline in total revenue.
Financial Highlights
Total Revenue: $1.963 million for the three months ended July 31, 2025, a decrease from $2.418 million in the same period last year, reflecting a decline in project revenue across Puerto Rico, United States, and European consulting markets.
Total Revenue: $6.851 million for the nine months ended July 31, 2025, a decrease from $7.176 million in the same period last year, with a notable increase in European market revenue offset by declines in other regions.
Gross Profit: $0.574 million for the three months ended July 31, 2025, representing 29.2% of total revenue, an increase from 26.3% in the same period last year, driven by improved margins in Puerto Rico and United States consulting markets.
Gross Profit: $2.161 million for the nine months ended July 31, 2025, representing 31.5% of total revenue, an increase from 24.9% in the same period last year, attributed to higher margins in key markets and a high-margin project in Europe.
Loss from Operations: $(0.314) million for the three months ended July 31, 2025, compared to $(0.382) million in the same period last year, indicating a reduction in operating losses.
Loss from Operations: $(0.504) million for the nine months ended July 31, 2025, compared to $(1.133) million in the same period last year, reflecting improved operational efficiency and cost management.
Net Loss: $(0.204) million for the three months ended July 31, 2025, an improvement from $(0.309) million in the same period last year, due to reduced operating expenses and increased other income.
Net Loss: $(0.100) million for the nine months ended July 31, 2025, an improvement from $(0.794) million in the same period last year, highlighting effective cost control and increased gross profit.
Basic and Diluted Loss Per Common Share: $(0.009) for the three months ended July 31, 2025, compared to $(0.014) in the same period last year, reflecting a reduction in net loss.
Basic and Diluted Loss Per Common Share: $(0.004) for the nine months ended July 31, 2025, compared to $(0.035) in the same period last year, indicating improved financial performance.
Business Highlights
Revenue Segments: The company operates in three reportable segments: Puerto Rico consulting, United States consulting, and Europe consulting. Each segment provides services primarily to the pharmaceutical, chemical, medical device, and biotechnology industries.
Geographical Performance: For the nine months ended July 31, 2025, the European market saw an increase in project revenue of approximately $1.0 million, while the Puerto Rico and US markets experienced declines of approximately $0.8 million and $0.4 million, respectively.
Geographical Performance: During the three months ended July 31, 2025, the Puerto Rico, United States, and European consulting markets experienced a decline in project revenue of approximately $0.2 million, $0.1 million, and $0.1 million, respectively.
Operational Efficiency: The company achieved a net increase in gross profit percentage points, mainly due to improved margins in the Puerto Rico and United States consulting markets, as well as a high-margin project in the European market.
Future Outlook: The company is actively pursuing expansion in the Puerto Rico, United States, Europe, and Brazil markets by strengthening its business development infrastructure and realigning business strategies to adapt to new opportunities and challenges.
Future Outlook: The company is assessing the impact of the One Big Beautiful Bill Act of 2025, which increases the effective tax rate on net CFC tested income, on its consolidated financial statements.
Market Strategy: The company markets its services through industry trade shows, professional conventions, industry publications, and company-provided seminars, with senior management actively involved in marketing to major accounts.
SEC Filing: Pharma-Bio Serv, Inc. [ PBSV ] - 10-Q - Sep. 15, 2025